Comparative Pharmacology
Head-to-head clinical analysis: STAPHCILLIN versus TOTACILLIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: STAPHCILLIN versus TOTACILLIN.
STAPHCILLIN vs TOTACILLIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Semisynthetic penicillin; inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation, and activating autolytic enzymes.
Bactericidal: inhibits cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation. Active against gram-positive bacteria and some gram-negative bacteria.
1-2 g IV every 4-6 hours.
250-500 mg orally every 6 hours or 1-2 g intravenously every 4-6 hours.
None Documented
None Documented
0.5-1 hour in adults with normal renal function; prolonged to 2-4 hours in renal impairment. Infants: 1-2 hours.
Terminal elimination half-life: 1.0-1.5 hours in normal renal function. Extended to 2-6 hours in renal impairment; requires dose adjustment when CrCl <30 mL/min.
Primarily renal (70-90% as unchanged drug via glomerular filtration and tubular secretion); minor biliary excretion (<5%) and fecal elimination (<1%).
Renal: 90-95% unchanged via glomerular filtration and tubular secretion. Biliary/fecal: <5% as unchanged drug and metabolites.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic